Search This Blog

Monday, December 9, 2024

Person of interest in Thompson kill caught with manifesto, gun, fake ID at McDonald’s

 A person of interest was nabbed Monday in the fatal shooting of UnitedHealthcare CEO Brian Thompson — busted possibly trying to use a fake ID in a McDonald’s, law enforcement sources said.

The man — who sources said is being eyed for the coldblooded, targeted execution in front of a Manhattan hotel last week — allegedly had a manifesto on him when he was taken into custody by cops in Altoona, Pa.

He also had a gun, silencer, four fake IDs and other items “consistent” with what authorities were looking for in the case, sources said.

The alleged killer is seen smiling in surveillance video.DCPI

Law enforcement was still trying to figure out the man’s real identity, sources said.

He was nabbed on a tip called in to local cops, who apprehended him, sources said.

The NYPD was on its way to Altoona late Monday morning, sources said.

The bust came amid a massive manhunt for the masked shooter who lay in wait outside the Hilton on Sixth Avenue where Thompson, 50, was set to speak at an investors’ conference Wednesday morning.

The chillingly efficient gunman snuck up behind Thompson on the sidewalk, pulled out what appeared to be a handgun with a silencer and calmly unloaded multiple shots at the CEO’s back, shocking surveillance footage showed.

The gunman shot Brian Thompson in the back outside the Hilton hotel on Wednesday morning.Obtained by NY Post
Thompson served as the CEO of UnitedHealthcare since 2021.Linkedin / Brian Thompson

Thompson dropped to the ground after he was hit in the back and right calf, with the gunman quickly running off before grabbing an e-bike and riding away.

Thompson was rushed to Mount Sinai hospital, where he was pronounced dead.

The execution prompted a massive manhunt and a steady drip of sometimes bizarre clues and revelations.

The shooter’s bullets found at the scene appeared to have the words “deny,” “depose” and “defend” written on them — a potential message from the killer that echoed the title of a book condemning the health care insurance industry’s practice of not paying claims.

Video uncovered during the investigation also revealed the suspected killer’s smiling face, as well as his potential connection to an Upper West Side hostel, where he is believed to have stayed before the murder.

A motive wasn’t immediately known.

NYPD Commissioner Jessica Tisch has told reporters that the shooter intentionally targeted Thompson — a father of two sons, whose wife said had been the target of recent threats over his job — as witnesses milled around the hotel.

“Many people passed the suspect, but he appeared to wait for his intended target,” she said. 

It is not immediately clear if anyone has claimed the $10,000 reward offered by the NYPD and CrimeStoppers.

Thompson’s wife, Paulette “Pauley” Thompson, 51, said that before the shooting, the family had received threats relating to her husband’s job leading America’s largest private insurer, NBC News reports.

Police say the suspect fired multiple times, hitting Thompson in the back and right calf.AP

“There had been some threats,” she said, according to NBC. “Basically, I don’t know, a lack of coverage? I don’t know details. I just know that he said there were some people that had been threatening him.” 

Law enforcement sources confirmed to The Post that UnitedHealthcare had told investigators about threats made against Thompson.

Thompson was promoted in 2021 to CEO of UnitedHealthcare, where he earned nearly $10 million the next year, according to the Economic Research Institute.

A backpack believed to have belonged to the suspect was found in Central Park last week.Obtained by NY Post

The shooting sent the investors’ conference, which Thompson was due to speak, into a panic, with witnesses saying the attendees left in shock and tears.

The UnitedHealth Group released a statement expressing shock at Thompson’s death.

“Brian was a highly respected colleague and friend to all who worked with him,” the statement reads.

Flags at the company’s corporate headquarters in Minnetonka, Minn., were flown at half-staff on Wednesday. 

“This is horrifying news and a terrible loss for the business and health care community in Minnesota.” Gov. Tim Walz said in a statement. “Minnesota is sending our prayers to Brian’s family and the UnitedHealthcare team.” 

https://nypost.com/2024/12/09/us-news/person-of-interest-nabbed-in-fatal-shooting-of-unitedhealthcare-ceo-brian-thompson-outside-nyc-hotel/

Merck Touts 100% Complete Response Rate for Anti-ROR1 ADC as First-Line Lymphoma

 

Analysts called the data “very competitive” but raised questions about safety. Merck gained ownership of the ADC when it acquired VelosBio in November 2020 for $2.75 billion.

Merck on Sunday unveiled initial data from the Phase II waveLINE-007 study, demonstrating that its investigational antibody-drug conjufate zilovertamab vedotin achieved a 100% complete response rate when used as part of a treatment regimen in patients with diffuse large B cell lymphoma.

The pharma presented these findings at the ongoing 66th annual meeting of the American Society of Hematology (ASH 2024), being held in San Diego.

In a note over the weekend, BMO Capital Markets analysts called data for Merck’s ADC “very competitive,” however noting that “safety remains more of a question” moving forward.

In the study, all 15 patients treated with 1.75 mg/kg of zilovertamab vedotin, in combination with the anti-cancer regimen R-CHP—cyclophosphamide, doxorubicin, prednisone and rituximab—reached complete response, as assessed using a PET scan and a CT or MRI scan.

At a higher dose level of 2 mg/kg, complete response rate (CRR) dipped slightly to 93.3%, before going back up to 100% in the six patients who were dosed at 2.25 mg/kg. The overall CRR at the end of the treatment period was 97.2%. At the time of the readout, median duration of response has not yet been reached for all patients.

As for safety, waveLINE-007 documented grade 3 to 4 treatment-related adverse events in 58% of patients, the most common of which were nausea, neutropenia, anemia and diarrhea. Serious treatment-related toxicities arose in 11%, most of whom were given the highest zilovertamab vedotin dose. None of the patients in the 1.75 mg/kg arm dropped out of the study, while one participant in the highest dose bracket had to discontinue, as deemed appropriate by their physician.

Based on these findings, Merck will take the 1.75 mg/kg dose of zilovertamab vedotin forward into Phase III testing.

Zilovertamab vedotin targets the ROR1 transmembrane protein, which is highly expressed in blood cancer cells. The ADC carries a monomethyl auristatin E payload, which when released inside the cell disrupts microtubules, prevents cell division and ultimately triggers cell death.

Merck gained ownership of zilovertamab vedotin in November 2020, when it bought San Diego biotech VelosBio for $2.75 billion. At the time, the ADC was still in early-to-mid-stage development, but Merck has since expanded the development program for zilovertamab vedotin. In addition to the , including the waveLINE-007, the company has two other ongoing trials in the same indication, diffuse large B cell lymphoma (DLBCL): the Phase II/III waveLINE-003 study for relapsed or refractory DLBCL and the Phase III waveLINE-010 trial in treatment-naive DLBCL patients.

https://www.biospace.com/drug-development/merck-touts-100-complete-response-rate-for-anti-ror1-adc-as-first-line-lymphoma-treatment

AbbVie's third successful Parkinson's trial sets the stage for an eventful 2025

 It's the latest victory for the biotech company in the space

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson's disease on Monday and said it's on track to seek approval for the drug from the Food and Drug Administration in 2025.

The North Chicago, Ill.-based biotech said a third Phase 3 trial evaluating tavapadon as a flexible-dose monotherapy in early Parkinson's disease met its primary and secondary endpoints, showing statistically significant results for each.

The primary endpoint was a reduction from baseline compared with placebo in the Movement Disorder Society-Unified Parkinson's disease Rating Scale, or MDS-UPDRS, the most widely used scale to measure motor function in patients with the neurological disorder. The company used doses of 5 to 15 milligrams once daily for a period of 26 weeks.

The secondary endpoint was an improvement in motor aspects of experiences of daily living compared with placebo.

"With these data in hand, we look forward to working with regulatory agencies to assess next steps, bringing us one step closer to providing tavapadon for those living with this chronic, debilitating disease," Primal Kaur, senior vice president for immunology, neuroscience, eye care and specialty development at AbbVie (ABBV), said in prepared remarks.

The safety profile was consistent with earlier trials, and most adverse events were mild to moderate in severity.

The company will submit the full trial results at a future medical meeting and then submit a new drug application to the FDA.

Tavapadon is the first and only selective D1/D5 receptor partial agonist under investigation for Parkinson's and is being studied both as a monotherapy and adjunctive therapy to levodopa, the current standard of care.

The trial involved 304 adults age 40 to 80, all of whom had a confirmed diagnosis.

Some 500,000 Americans are living with Parkinson's, according to the National Institutes of Health, but because some cases are misdiagnosed, the true number is expected to be at least 1 million.

In October, AbbVie won FDA approval for the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's.

The treatment allows patients to have a steady flow of dopamine, which is needed to cope with the tremors, stiffness and slow movement that often come with Parkinson's disease.

https://www.morningstar.com/news/marketwatch/2024120986/abbvies-third-successful-parkinsons-trial-sets-the-stage-for-an-eventful-2025

Illegal Aliens Already Self-Deporting In Anticipation Of Second Trump Presidency

 by Eric Lendrum via American Greatness,

With less than two months before President-elect Donald Trump returns to the White House, a number of illegal aliens attempting to enter the United States are already abandoning their attempts to cross the border and are returning to their home countries.

As reported by Fox News, up to 100 illegal aliens in Mexico have requested “voluntary return” to their countries of origin, according to Mexican officials.

The illegals in question are either paying the costs of return out of their own pocket, or seeking state funds to do so.

Many of the illegals specifically cited Trump’s impending return to office and his plans to crack down on immigration as their reasons for changing their minds.

President-elect Trump has vowed to eliminate a government-approved app called “CBP One,” which has allowed illegals to digitally apply for, and be swiftly granted, asylum without ever appearing in an immigration court, thus fast-tracking amnesty on a massive scale. He also pledged to re-implement the “Remain in Mexico” policy, a successful immigration policy from his first term that forced illegals to stay in Mexico while their applications for asylum or citizenship were processed.

“I cry every day and ask God to take me back, I don’t want to be here anymore… this is horrible,” said one illegal.

“I am traumatized. If I don’t get the appointment, I will go back,” said another illegal.

In addition to cracking down on the illegals themselves, the second Trump Administration also plans to take the fight directly to the cartels that have facilitated mass smuggling of illegals for profit.

“They have killed more Americans than every terrorist organization in the world and Trump is committed to calling them terrorist organizations and using the full might of the United States Special Operations to take them out,” said Tom Homan, the incoming Border Czar for the second Trump Administration.

https://www.zerohedge.com/political/illegal-aliens-already-self-deporting-anticipation-second-trump-presidency

Penny not guilt on lesser charge

 Daniel Penny has been found not guilty.

It comes after jurors told the court Friday morning they couldn't reach an agreement on the top charge, second-degree manslaughter, and prosecutors moved to dismiss it, prompting the judge to controversially allow them to only deliberate the second charge.

Penny, a 26-year-old Marine veteran and architecture student, was charged with manslaughter and criminally negligent homicide for the subway chokehold death of Jordan Neely, a 30-year-old homeless man with schizophrenia who barged onto the train shouting death threats while high on a type of synthetic marijuana known as K2.

The incident happened on May 1, 2023. 


Daniel Penny arrives at the Manhattan Criminal Courthouse building

Daniel Penny arrives at the Manhattan Criminal Courthouse building in New York City on Monday, Nov. 25, 2024 for the start of closing arguments. (Rashid Umar Abbasi for Fox News Digital)

Just three days earlier, a straphanger had been stabbed with an ice pick on a J train, according to reports from the time. It was about a month after a PBS reporter got sucker punched on a No. 4 train. There was a shove a week before that, and the victim hit the side of a moving R train and survived.

In that climate of fear, witnesses said they were terrified by Neely, who shouted death threats at them.

Witness Ivette Rosario, a 19-year-old student, testified that Neely shouted someone would "die that day."

"I got scared by the tone that he was saying it," she said. "I have seen situations, but not like that.

Jordan Neely is pictured before going to see the Michael Jackson movie

Jordan Neely is pictured before going to see the Michael Jackson movie, "This is It," outside the Regal Cinemas on 8th Avenue and 42nd Street in Times Square, New York, in 2009.  (Andrew Savulich/New York Daily News/Tribune News Service via Getty Images)

Penny, in a voluntary interview with police after the incident, raised concerns about a series of subway shoving incidents involving mentally ill people on the city's transit system.

"He was talking gibberish...but these guys are pushing people in front of trains and stuff," he told detectives. There were more than 20 subway shoves in the year before Penny's encounter with Neely.

He was released without charges after the interview.

Daniel Penny arrives at court in New York City for the trial in the chokehold death of Jordan Neely on a New York City Subway car

Daniel Penny arrives at Manhattan Supreme Court in New York, NY on Tuesday, Dec. 3, 2024. (Rashid Umar Abbasi for Fox News Digital)

But Manhattan District Attorney Alvin Bragg's office secured a grand jury indictment days later, and Penny was arrested on May 12.

Jurors deliberated for a little less than four hours Tuesday and all day Wednesday, sending several notes to the judge. Among the items they asked for were videos of the chokehold and of Penny's interview with police, as well as the judge's instructions regarding justification for physical force and the definitions of recklessness and negligence. 

Penny faces a maximum sentence of four years in prison if convicted of the lesser charge.


Witnesses testified that Neely's threats scared them more than a typical subway outburst would. They were thankful for Penny's intervention.

Neely had a lengthy criminal record, an active arrest warrant, a history of psychosis and was high on K2, a synthetic form of marijuana that pathologists described as a stimulant. He also had the sickle cell trait genetic disorder.

https://www.foxnews.com/us/daniel-penny-trial-jury-reaches-verdict-subway-chokehold-case

Idexx Ups Share Repurchase Program Authorization

 IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that the Company’s Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company’s common stock. Repurchases may be made at management’s discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. These shares are in addition to the 1.3 million shares remaining under the Company’s ongoing share repurchase program as of December 3, 2024, pursuant to previous Board authorizations. The share repurchase program has no specified expiration date and may be suspended or discontinued at any time.

https://www.businesswire.com/news/home/20241208581314/en

Merck Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer

 On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial.

The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza (olaparib), with or without bevacizumab, as a first-line treatment for BRCA non-mutated advanced epithelial ovarian cancer met its primary endpoint of progression-free survival.


At the final analysis conducted by an independent Data Monitoring Committee, the Keytruda plus Lynparza regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for these patients compared to chemotherapy alone.

The study did not reach its secondary endpoint of overall survival. The role of keytruda in the intention-to-treat population remains uncertain at this time.

In the U.S., Lynparza has three approved indications in ovarian cancer. Keytruda is not approved to treat ovarian cancer.

Sunday, Merck announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) for previously untreated diffuse large B-cell lymphoma (DLBCL).

At a pre-planned analysis, zilovertamab vedotin in combination with R-CHP achieved a 100% (n=15) complete response (CR) rate in patients treated with zilovertamab vedotin at 1.75 mg/kg.

Based on the data, the study has established 1.75 mg/kg as the recommended Phase 3 dose of zilovertamab vedotin.

The efficacy results showed a complete response was achieved in combination with R-CHP in 100% (n=15) of patients receiving the 1.75 mg/kg dose of zilovertamab vedotin, 93.3% (n=14) of patients receiving the 2.0 mg/kg dose, and 100% (n=6) of patients receiving the 2.25 mg/kg dose.

The total complete response rate at the end of treatment was 97.2%. The median follow-up for all patients was 17.6 months.

The objective response rate was 100% for patients receiving the 1.75 mg/kg dose, 93.3% for patients receiving the 2.0 mg/kg dose, and 100% for patients receiving the 2.25 mg/kg dose, all combined with R-CHP.

The median duration of response has not been reached for all patients, and the total 12-month duration of response was 93.5%.

Based on the data, the recommended zilovertamab vedotin dose was determined to be 1.75 mg/kg.


https://finance.yahoo.com/news/merck-reveals-mixed-data-keytruda-155051438.html